The COVID-19 pandemic had world wide an enormous impact on the complete global population and all daily activities. Not only in the work related situation, but also in the private. Fear to become ...infected, or infect third parties (family and other patients) is present, and in the same time organizing an apheresis unit country wide is a challenge.
Editor’s bio: Dr. Hans Vrielink Vrielink, Hans
Transfusion and apheresis science,
April 2023, 2023-04-00, 20230401, Letnik:
62, Številka:
2
Journal Article
Covid-19 Convalescent Plasma (CCP) was one of alternative therapy for Covid-19 patients. The use of convalescent plasma as an adjunct therapy must consider its efficacy, benefits, and risk, both for ...the patient and the donor. Convalescent Plasma was produced from purified human plasma. Convalescent Plasma was a passive immunity which provide active antibodies. CCP give immunity to the patient through the transfusion of a survivor’s antibodies. We were reporting a case of male CCP donor with long existence of SARS-Cov-2. This donor performed up to 16 donations, which was an unusual case in CCP donor. The SARS-CoV-2 antibody titer was analyzed using Elecsys® Anti-SARS-CoV-2 (Roche Diagnostics). The SARS-CoV-2 antibody showed high level of total SARS-CoV-2 antibodies, with the Cut off Indexes (COI) anti SARS-Cov-2 antibody were still quite high (132 U/mL). The highest donor antibody COI (204.6 U/mL) was seen in 11th donation at 6 months after recovery, while the lowest antibody COI (130.8 U/mL) was in 15th donation at 7 months after recovering. Evaluation of donor health status were performed after the 16th donation and analyzed as well. In conclusion, 16 CCP donations of 600 mL resulting in 48 units of 200 mL plasma in 8 months was safe for the donor, with the SARS-Cov-2 antibody titer remained high in the whole period.
Next president of the WAA Vrielink, Hans
Transfusion and apheresis science,
October 2020, 2020-10-00, 20201001, Letnik:
59, Številka:
5
Journal Article
Many studies already reported on the association between patient characteristics on the severity of COVID-19 disease outcome, but the relation with SARS-CoV-2 antibody levels is less clear. To ...investigate this in more detail, we performed a retrospective observational study in which we used the IgG antibody response from 11,118 longitudinal antibody measurements of 2,082 unique COVID convalescent plasma donors. COVID-19 symptoms and donor characteristics were obtained by a questionnaire. Antibody responses were modelled using a linear mixed-effects model. Our study confirms that the SARS-CoV-2 antibody response is associated with patient characteristics like body mass index and age. Antibody decay was faster in male than in female donors (average half-life of 62 versus 72 days). Most interestingly, we also found that three symptoms (headache, anosmia, nasal cold) were associated with lower peak IgG, while six other symptoms (dry cough, fatigue, diarrhoea, fever, dyspnoea, muscle weakness) were associated with higher IgG concentrations.
In patients with an end-stage renal disease, dialysis a or kidney transplant are required to prolong live. For survival of the transplanted kidney, besides the HLA-system, the ABO blood type of donor ...and patient is also of importance. When the donor organ is derived from a living donor, time can be available prior to the transplant to reduce blood type AB antibodies in case of ABO major incompatibility between organ donor and recipient by double filtration apheresis.
PDF